RPG Life Sciences Q3 net profit rises 14% yoy to Rs14.63cr; Stock ends lower

27 Jan 2022 , 03:40 PM

RPG Life Sciences Limited on Tuesday reported a 14% yoy rise in net profit to Rs14.63cr for the third quarter ended December 31, 2021. The company had reported a net profit of Rs12.87cr in the same period of the previous fiscal.

Revenue from operations rose 7% yoy to Rs115.58cr in the third quarter as compared to Rs107.760cr in the year-ago period, the company said in a regulatory filing.

For 9MFY22, net profit increased to Rs43.96cr from Rs33.08 in 9MFY21. Revenue rose 13% yoy to Rs336.36cr from Rs296.38cr in 9MFY21. The company continues to remain debt free with highest-ever net cash flow generated from operations in 9MFY22.

RPG Life Sciences Ltd ended at Rs594.90 per piece down by Rs35.45 or 5.62% from its previous closing of Rs630.35 per piece on the BSE.

“Domestic formulations business recorded a robust growth both in value and volumes – significantly better than the market. While life cycle management initiatives helped legacy brands register healthy growth, our new product portfolio is also witnessing impressive uptake. We successfully forayed into a new segment-Rheumatology, which is strengthening our endeavour of expanding into Specialty segment,” RPG Life Sciences Managing Director Yugal Sikri said.